絞り込み

18438

広告

温暖化対策強化、100人分訴え (毎日新聞)

若者グループが25日夕、政府などに地球温暖化対策の強化を訴える活動を全国各地で行った。東京都千代田区の国会前では、「迫り来るタイムリミット」「石炭だめ」などのメ...

  1. 新型コロナ GoTo事業者、来月募集 「...
  2. 検証:異常気象、新たな日常 米で熱波/北...
  3. 新型コロナ 全国新たに576人 (毎日新...
  4. 新型コロナ 接種主体は市町村に ワクチン...

ニュース一覧

How I treat acute myeloid leukemia in the era of new drugs.

著者 DiNardo CD , Wei AH
Blood.2019 Nov 25 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (14view , 0users)
The treatment landscape for acute myeloid leukemia (AML) has changed substantially since 2017. A host of new targeted drugs have emerged onto the scene, including venetoclax to target BCL-2, midostaurin and gilteritinib to target FLT3 and ivosidenib and enasidenib to target mutant IDH1 and IDH2, respectively. Other additions include re-approval of gemtuzumab ozogomycin to target CD33, glasdegib to target the hedgehog pathway and a liposomal formulation of daunorubicin and cytarabine (CPX-351). AML is genomically heterogeneous and has a tendency to evolve, particularly under selective treatment pressure. For decades, treatment decisions have largely centred around chemotherapy drug intensity. Physicians now have access to an increasing number of drugs with novel mechanisms of action and distinctive side-effect profiles. Key issues faced by haematologists in this era of new drugs include 1) the timely identification of actionable mutations, not just at diagnosis but also at relapse, 2) deciding which drug to use when several therapeutic options are available and 3) the need for increased awareness of how to anticipate, mitigate and manage common complications associated with these new agents. This new addition to the How I Treat series will utilize three case presentations to discuss some of the new treatment challenges encountered in the management of AML, with the goal of providing practical guidance to aid the practising physician.
PMID: 31765470 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード